BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17307126)

  • 1. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
    Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
    Nayak T; Norenberg J; Anderson T; Atcher R
    Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
    Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
    Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.
    Nayak TK; Atcher RW; Prossnitz ER; Norenberg JP
    Nucl Med Biol; 2008 Aug; 35(6):673-8. PubMed ID: 18678352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
    Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
    PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
    Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
    J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
    Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose rate dependence of the relative biological effectiveness of 103Pd for continuous low dose rate irradiation of BA1112 rhabdomyosarcoma cells in vitro relative to acute exposures.
    Nath R; Bongiorni P; Chen Z; Gragnano J; Rockwell S
    Int J Radiat Biol; 2005 Sep; 81(9):689-99. PubMed ID: 16368647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
    Ginj M; Hinni K; Tschumi S; Schulz S; Maecke HR
    J Nucl Med; 2005 Dec; 46(12):2097-103. PubMed ID: 16330576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes.
    Dadachova E; Howell RW; Bryan RA; Frenkel A; Nosanchuk JD; Casadevall A
    J Nucl Med; 2004 Feb; 45(2):313-20. PubMed ID: 14960655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.
    Elgqvist J; Timmermand OV; Larsson E; Strand SE
    Anticancer Res; 2016 Jan; 36(1):103-9. PubMed ID: 26722033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
    Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
    Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
    PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor.
    Akinlolu O; Ottolino-Perry K; McCart JA; Reilly RM
    Cancer Biother Radiopharm; 2010 Jun; 25(3):325-33. PubMed ID: 20578838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells.
    Fueger BJ; Hamilton G; Raderer M; Pangerl T; Traub T; Angelberger P; Baumgartner G; Dudczak R; Virgolini I
    J Nucl Med; 2001 Dec; 42(12):1856-62. PubMed ID: 11752085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro.
    Oddstig J; Bernhardt P; Nilsson O; Ahlman H; Forssell-Aronsson E
    Nucl Med Biol; 2006 Oct; 33(7):841-6. PubMed ID: 17045163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.